enGene Holdings Inc. (NASDAQ:ENGN) Given Average Rating of “Buy” by Brokerages

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have been given a consensus recommendation of “Buy” by the twelve ratings firms that are covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $26.40.

A number of brokerages recently weighed in on ENGN. Raymond James began coverage on shares of enGene in a report on Wednesday, November 27th. They set an “outperform” rating and a $23.00 target price for the company. JMP Securities restated a “market outperform” rating and set a $18.00 target price on shares of enGene in a report on Monday, December 23rd. Citizens Jmp upgraded shares of enGene to a “strong-buy” rating in a report on Monday, November 18th. HC Wainwright initiated coverage on shares of enGene in a report on Monday, December 23rd. They set a “buy” rating and a $25.00 target price for the company. Finally, Piper Sandler initiated coverage on shares of enGene in a research report on Tuesday. They issued an “overweight” rating and a $26.00 price target for the company.

Institutional Investors Weigh In On enGene

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ENGN. Wolverine Asset Management LLC purchased a new stake in enGene in the 3rd quarter worth approximately $37,000. Point72 Asset Management L.P. lifted its position in enGene by 1,410.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock worth $4,376,000 after buying an additional 619,100 shares in the last quarter. Franklin Resources Inc. lifted its position in enGene by 48.7% in the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock worth $7,854,000 after buying an additional 389,918 shares in the last quarter. Vontobel Holding Ltd. purchased a new stake in enGene in the 4th quarter worth approximately $69,000. Finally, Blue Owl Capital Holdings LP lifted its position in enGene by 3.3% in the 4th quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company’s stock worth $21,014,000 after buying an additional 101,006 shares in the last quarter. Hedge funds and other institutional investors own 64.16% of the company’s stock.

enGene Trading Up 2.1 %

enGene stock opened at $6.03 on Wednesday. The firm has a 50 day simple moving average of $6.83 and a 200-day simple moving average of $7.23. The company has a debt-to-equity ratio of 0.08, a current ratio of 16.87 and a quick ratio of 16.87. The stock has a market capitalization of $266.43 million, a PE ratio of -10.39 and a beta of -0.65. enGene has a 12-month low of $4.42 and a 12-month high of $18.40.

enGene (NASDAQ:ENGN) last posted its quarterly earnings data on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.40) by $0.06. As a group, equities research analysts expect that enGene will post -1.57 EPS for the current fiscal year.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.